Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

X4 Pharmaceuticals (XFOR) Tax Provisions (2020 - 2025)

X4 Pharmaceuticals' Tax Provisions history spans 6 years, with the latest figure at -$30000.0 for Q3 2025.

  • For Q3 2025, Tax Provisions fell 300.0% year-over-year to -$30000.0; the TTM value through Dec 2025 reached $41000.0, down 86.77%, while the annual FY2025 figure was $41000.0, 86.77% down from the prior year.
  • Tax Provisions reached -$30000.0 in Q3 2025 per XFOR's latest filing, down from $37000.0 in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $258000.0 in Q4 2024 to a low of -$30000.0 in Q3 2025.
  • Average Tax Provisions over 5 years is $24947.4, with a median of $15000.0 recorded in 2023.
  • Peak YoY movement for Tax Provisions: tumbled 750.0% in 2022, then soared 681.82% in 2024.
  • A 5-year view of Tax Provisions shows it stood at $3000.0 in 2021, then soared by 366.67% to $14000.0 in 2022, then skyrocketed by 135.71% to $33000.0 in 2023, then skyrocketed by 681.82% to $258000.0 in 2024, then tumbled by 111.63% to -$30000.0 in 2025.
  • Per Business Quant, the three most recent readings for XFOR's Tax Provisions are -$30000.0 (Q3 2025), $37000.0 (Q2 2025), and $34000.0 (Q1 2025).